AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...

AstraZeneca acquires EsoBiotec for $1 billion to enhance cancer treatment capabilities, with potential for revolutionary cell therapy.

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody ...

AstraZeneca entered into a definitive agreement to acquire Belgian cell therapy developer EsoBiotec. AstraZeneca continues to bet big on cell therapy. The Big Pharma company entered into a ...

Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...